Frizzled receptor 1; Frizzled receptor 2; Frizzled receptor 5; Frizzled receptor 7; Frizzled receptor 8 (FZD1; FZD2; FZD5; FZD7; FZD8)

Frizzled receptors 1, 2, 5, 7, and 8 are integral membrane proteins and members of the class F GPCR superfamily, sharing a characteristic structure with an N-terminal cysteine-rich domain (CRD) for ligand binding and a seven-transmembrane (7TM) domain. They serve as principal receptors for Wnt proteins, activating canonical (β-catenin-dependent) and non-canonical signaling pathways. These receptors critically regulate cell fate, proliferation, differentiation, and polarity in embryonic development and adult tissue homeostasis. Aberrant signaling through these FZDs is implicated in cancer progression, metastasis, fibrosis, neurodevelopmental and neurodegenerative diseases, making them important therapeutic targets. Current drug development approaches target FZDs with small molecules, antibodies, and surrogate ligands, but clinical translation faces challenges due to widespread physiological functions and pathway redundancy

Other names

Frizzled homolog 1/2/5/7/8Fz1; Fz2; Fz5; Fz7; Fz8Human homologs typically cited with the prefix "h" (hFZD1, etc.)

Inhibition of Wnt binding to the receptor (antagonists, antibodies) Promotion of receptor dimerization/co-receptor interaction (agonists, surrogates) Modulation of downstream β-catenin-dependent or independent signaling Disruption of receptor trafficking and membrane clustering